Drugs struggling post-PBAC

Eight drugs recommended by the PBAC in 2023 have recently been marked as 'inactive,' signalling that sponsors are struggling to agree on the committee's conditions for PBS listing.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here